Tests INCB161734 in adults with advanced solid tumors carrying a KRAS G12D mutation
Tests INCB161734, alone or with other cancer drugs, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Key facts
- Where
- Chiba and Tokyo, JapanSee the 2 sites
- Phase
- Phase 1
Where in Japan
- National Cancer Center Hospital EastChiba, JapanTaking people
- The Cancer Institute Hospital of JFCRTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06179160EU 2023-507091-47-00
- Record updated
- 22 July 2026
- Original description
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Inclusion: ≥18 years old; Locally advanced or metastatic solid tumor with KRAS G12D mutation; For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome; Cohort specific requirements aas defined in the protocol; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion: Prior treatment with any KRAS G12D inhibitor; Known additional invasive malignancy within 1 year of the first dose of study drug; History of organ transplant, including allogeneic stem cell transplantation; Significant, uncontrolled medical condition; History or presence of an ECG abnormality; Inadequate organ function; Other protocol-defined Inclusion/Exclusion Criteria may apply.